Evidence map›Paper›PMID 29546098›Full record

ReviewAIMS public health2015

Immunotherapy in Melanoma, Gastrointestinal (GI), and Pulmonary Malignancies.

Alexander B Dillon, Kevin Lin, Andrew Kwong, Susana Ortiz

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in AIMS public health, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Alexander B DillonMount Zion Cancer Research Center, Department of Dermatology, University of California San Francisco, CA 94141, USA.
Kevin LinMount Zion Cancer Research Center, Department of Dermatology, University of California San Francisco, CA 94141, USA.
Andrew KwongMount Zion Cancer Research Center, Department of Dermatology, University of California San Francisco, CA 94141, USA.
Susana OrtizMount Zion Cancer Research Center, Department of Dermatology, University of California San Francisco, CA 94141, USA.

Funding

Role of KIT in Early Melanoma DevelopmentK08CA155035 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ORTIZ URDA, SUSANA · 2011 to 2015
$610k
NCI NIH HHS K08 CA155035
6 · The paper itself

Abstract

Oncologic immunotherapy involves stimulating the immune system to more effectively identify and eradicate tumor cells that have successfully adapted to survive the body's natural immune defenses. Immunotherapy has shown great promise thus far by prolonging the lives of patients with a variety of malignancies, and has added a crucial new set of tools to the oncologists' armamentarium. The aim of this paper is to provide an overview of immunotherapy treatment options that are currently available and under active research for melanoma, gastrointestinal (esophageal, gastric, pancreatic, and colorectal), and pulmonary malignancies. Potential biomarkers that may predict favorable responses to immunotherapies are discussed where applicable, as are future avenues of research in this rapidly evolving field.

Indexed as

adoptive cell therapyanti-CTLA-4anti-PD-1colorectal canceresophageal cancergastric cancerIL-2immunotherapylung cancermelanoma

Identifiers

PMID29546098
PMCPMC5690372

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.